文献速递消化、代谢与肾脏急症心脑血管急症

卡格列净与2型糖尿病合并肾病患者的肾脏结局

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
PubMed 文献 · N Engl J Med · 2019-04-14
一句话结论在2型糖尿病合并白蛋白尿性慢性肾脏病患者中,卡格列净100 mg每日一次较安慰剂降低主要复合肾脏终点风险30%(HR 0.70)。

CREDENCE为双盲随机试验,纳入2型糖尿病合并白蛋白尿性慢性肾脏病、eGFR 30至<90 ml/min/1.73 m²且尿白蛋白/肌酐比值>300至5000 mg/g、已接受肾素-血管紧张素系统阻断治疗的患者,随机接受卡格列净100 mg每日一次或安慰剂。中位随访2.62年时因中期分析提前终止,共4401例患者随机化。卡格列净组主要复合终点(终末期肾病、血肌酐翻倍或肾脏/心血管死亡)事件率43.2 vs 安慰剂组61.2/1000患者年(HR 0.70;95%CI 0.59–0.82;P=0.00001),肾脏特异性复合终点HR 0.66,终末期肾病HR 0.68,心血管死亡/心梗/卒中HR 0.80,心衰住院HR 0.61;截肢与骨折无显著差异。

要点

  • 卡格列净100 mg每日一次使主要复合终点(终末期肾病、血肌酐翻倍、肾脏或心血管死亡)风险较安慰剂降低30%(HR 0.70;95%CI 0.59–0.82;P=0.00001),事件率43.2 vs 61.2/1000患者年。
  • 肾脏特异性复合终点(终末期肾病、血肌酐翻倍或肾脏死亡)风险降低34%(HR 0.66;95%CI 0.53–0.81;P<0.001)。
  • 终末期肾病风险降低32%(HR 0.68;95%CI 0.54–0.86;P=0.002)。
  • 心血管死亡、心肌梗死或卒中风险降低(HR 0.80;95%CI 0.67–0.95;P=0.01),心衰住院风险降低(HR 0.61;95%CI 0.47–0.80;P<0.001)。
  • 截肢与骨折发生率无显著差异。

适用人群与场景

  • 2型糖尿病合并白蛋白尿性慢性肾脏病患者,eGFR 30至<90 ml/min/1.73 m²,尿白蛋白/肌酐比值>300至5000 mg/g,且已接受肾素-血管紧张素系统阻断治疗。

诊断标准与关键阈值

  • 入组标准:2型糖尿病,eGFR 30至<90 ml/min/1.73 m²,尿白蛋白(mg)/肌酐(g)比值>300至5000,正在接受肾素-血管紧张素系统阻断治疗。

处置流程与药物剂量

  • 卡格列净100 mg口服每日一次,对照为安慰剂。

研究设计与关键结果

  • 研究类型:双盲随机试验;样本量4401例;中位随访2.62年;因中期分析按数据与安全监查委员会建议提前终止。
  • 主要终点(终末期肾病[透析、移植或持续eGFR<15 ml/min/1.73 m²]、血肌酐翻倍或肾脏/心血管死亡复合终点):卡格列净组事件率43.2/1000患者年 vs 安慰剂组61.2/1000患者年,风险降低30%(HR 0.70;95%CI 0.59–0.82;P=0.00001)。
  • 肾脏特异性复合终点(终末期肾病、血肌酐翻倍或肾脏死亡):风险降低34%(HR 0.66;95%CI 0.53–0.81;P<0.001)。
  • 终末期肾病:风险降低32%(HR 0.68;95%CI 0.54–0.86;P=0.002)。
  • 心血管死亡、心肌梗死或卒中:风险降低(HR 0.80;95%CI 0.67–0.95;P=0.01)。
  • 心衰住院:风险降低(HR 0.61;95%CI 0.47–0.80;P<0.001)。
  • 截肢与骨折发生率:无显著差异。

证据类型、等级与局限

  • 证据类型:随机对照试验(CREDENCE,NCT02065791),由Janssen Research and Development资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对2型糖尿病合并白蛋白尿性慢性肾脏病、eGFR 30至<90 ml/min/1.73 m²且尿白蛋白/肌酐比值>300至5000 mg/g、已接受肾素-血管紧张素系统阻断治疗的患者,卡格列净100 mg每日一次可降低肾脏衰竭与心血管事件风险。
  • 截肢与骨折发生率在卡格列净组与安慰剂组间无显著差异。

指南或共识出处

  • CREDENCE试验,ClinicalTrials.gov注册号NCT02065791,发表于N Engl J Med。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.

METHODS: In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin-angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically.

RESULTS: The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P = 0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P = 0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P = 0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture.

CONCLUSIONS: In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; CREDENCE ClinicalTrials.gov number, NCT02065791.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019. PMID: 30990260. doi:10.1056/NEJMoa1811744

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。